Trials / Completed
CompletedNCT00396656
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atenolol | 100 mg tablets orally once a day (od) in the morning. |
| DRUG | Hydrochlorothiazide (HCTZ)) | 12.5 or 25 mg tablets orally once a day (od) in the morning. |
| DRUG | Valsartan | 80 mg, 160 mg, or 320 mg tablets orally once a day in the morning |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2006-11-07
- Last updated
- 2011-06-06
- Results posted
- 2011-06-06
Locations
2 sites across 2 countries: Germany, Switzerland
Source: ClinicalTrials.gov record NCT00396656. Inclusion in this directory is not an endorsement.